Adding everolimus (Afinitor, Novartis), a mammalian target of rapamycin (mTOR) inhibitor, to exemestane (Aromasin) significantly improved progression-free survival of postmenopausal women with advanced estrogen receptor–positive breast cancer vs exemestane alone, according to updated findings from a randomized trial reported here at the 34th Annual San Antonio Breast Cancer Symposium....
BOLERO-2
Among 724 women, median progression-free survival (PFS) with the addition of everolimus to exemestane was 7.4 months, compared with 3.2 months for exemestane alone (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.36 - 0.53; P < .001), reported Gabriel N. Hortobagyi, MD, on behalf of investigators in the BOLERO-2 (Breast Cancer Trials of Oral Everolimus-2) trial.
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.